SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA approval of competing RRP treatment Voceryq has put Precigens PAPZIMEOS in focus, with traders debating whether the new entrant will erode its sales. Bears see a direct competitive threat, while bulls point to PAPZIMEOS full approval and commercial head start and question Inovios ability to commercialize an accelerated-approval drug.

Compound (COMP) is a cryptocurrency and operates on the Ethereum platform. Compound has a current supply of 10,000,000 with 9,999,999.99995246 in circulation. The last known price of Compound is 20.49527411 USD and is down -2.02 over the last 24 hours. It is currently trading on 652 active market(s) with $25,001,434.49 traded over the last 24 hours. More information can be found at https://www.compound.xyz/.

Compound

Discussion centers on Compounds institutional-market launch and treasury-backed institutional finance push, which traders view as a potential catalyst alongside the protocols planned upgrades. Optimism about COMPs limited supply and a possible breakout is tempered by complaints that it continues to lag other crypto assets.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Stockholm, Sweden.

Spotify Technology S.A.

Spotifys Q3 report and stronger-than-expected Q4 profit outlook are driving attention, with shares rising despite revenue and EPS misses. Traders are focused on subscriber growth and improved margins, while some question the rally given the earnings shortfall and higher expenses.

Twilio, Inc. engages in the development of communications software, cloud-based platforms, and services. It operates through Twilio Communications and Twilio Segments. The Twilio Communications segment includes the platforms Messaging and Voice. The Twilio Segment involves Segment, Engage, Flex, Email, and others. The company was founded by John Wolthuis, Jeffery G. Lawson, and Evan Cooke in March 2008 and is headquartered in San Francisco, CA.

Twilio Inc - Ordinary Shares Class A

Twilio Inc

Twilios shares sold off despite a quarterly earnings beat as its outlook signaled slower organic growth, prompting concerns about deceleration and softer guidance. Traders are split between viewing the drop as an overreaction and buy-the-dip opportunity, and seeing the slower outlook as outweighing the results; some remain positive on Twilios longer-term AI communications potential.

iShares Trust - iShares China Large-Cap ETF

iShares China Large-Cap ETF

FXI is drawing attention amid a broad selloff in Chinese equities, with traders citing the CSI 300s bear-market decline, weak domestic demand and added uncertainty around AI export restrictions. The community is divided between warnings of a prolonged downturn and views that beaten-down China shares may be nearing a base.

Zebec Network (ZBCN) is a cryptocurrency launched in 2022and operates on the Solana platform. Zebec Network has a current supply of 99,998,768,617.445403. The last known price of Zebec Network is 0.00204055 USD and is down -0.09 over the last 24 hours. It is currently trading on 133 active market(s) with $10,537,951.06 traded over the last 24 hours. More information can be found at https://zebec.io/.

Zebec Network

Attention is centered on Zebecs payroll and payments integrations, particularly the MoneyGram/Stellar connection and a reported Germany/AllUnity deployment, which bullish traders view as adoption catalysts. Skeptics counter that partnership news has yet to translate into sustained token demand or price strength, while speculation about additional Robinhood or Ripple links remains unconfirmed.

OpenAI

OpenAIs potential IPO is driving attention, with traders debating reports that the listing could slip to 2027 amid market volatility and heightened safety and legal scrutiny. The discussion is split between enthusiasm for a major AI listing and skepticism about OpenAIs valuation, cash burn, and ability to sustain growth against competitors.

Artificial Superintelligence Alliance (FET) is a cryptocurrency launched in 2018. Artificial Superintelligence Alliance has a current supply of 2,714,384,546.672 with 2,419,135,848.3909366 in circulation. The last known price of Artificial Superintelligence Alliance is 0.16707757 USD and is up 1.84 over the last 24 hours. It is currently trading on 592 active market(s) with $193,186,396.23 traded over the last 24 hours. More information can be found at https://superintelligence.io/.

Fetch.ai

FETs price action and its place in the AI-crypto trade dominate the discussion, with traders watching for a breakout and describing relative strength during broader market weakness. Bullish dip-buying and accumulation hopes coexist with frustration over lagging performance and concern that Bitcoin weakness could weigh on the token.

Invesco Exchange-Traded Fund Trust - Invesco S&P 500 Equal Weight ETF

Invesco S&P 500 Equal Weight ETF

RSP is drawing attention as a gauge of whether the S&P 500 rally is broadening beyond mega-cap tech, with traders highlighting its relative strength and recent highs as evidence of rotation into the average stock. Others warn that participation remains uneven and question whether the rotation can persist, especially as technology leadership shifts.

Crocs, Inc. engages in the design, development, manufacture, worldwide marketing, sale, and distribution of lifestyle footwear and accessories. It operates through the Crocs Brand and HEYDUDE Brand segments. The Crocs Brand segment refers to the United States, South Korea, China, Japan, Singapore, Canada, Germany, Great Britain, France, Malaysia, Australia, Puerto Rico, the Netherlands, Australia, India, and Ireland. The HEYDUDE Brand segment focuses on the United States. The company was founded by Scott Seamans, George B. Boedecker, Jr., and Lyndon V. Hanson III in 2002 and is headquartered in Broomfield, CO.

Crocs Inc

Crocs is drawing attention after quarterly results topped expectations and management raised its outlook, citing a continuing HEYDUDE recovery and steady demand for its core brand; the news fueled a sharp rally. Traders are cheering the breakout, while others warn of profit-taking and point to continued weakness in North American sales.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Regeneron is drawing attention after a strong third-quarter earnings and revenue beat, with traders crediting growth from Dupixent and Eylea HD for the sharp rally. The breakout to a new 52-week high has fueled bullish momentum and options-flow chatter, while some traders are watching whether the gains hold.

REGN Q3 Earnings Beat on Dupixent Profits & Eylea HD Growth, Stock Up

Regeneron's Q3 earnings and revenues beat estimates, fueled by strong Dupixent profits, Eylea HD growth and robust Libtayo demand. Stock up. 

ALNY Stock Down 25% Despite Q3 Earnings Beat on Demand Growth Concerns

Alnylam's shares fall 25% despite Q3 beat as slower Amvuttra patient starts and demand concerns weigh on investor sentiment.

Pre-Markets Spooked on Questions Regarding AI, Oil Prices

Led by the Nasdaq shedding another -2.5% (-750 points) ahead of the open, the stock market is looking at a down week of trading.

Sanofi Q3 Earnings & Sales Beat, 2026 View Up, Shares Rise

SNY beats Q3 earnings and sales estimates as Dupixent drives growth and the company raises its 2026 outlook for sales and business EPS.

REGN Stock Hits 2-Year Highs Pre-Market: CFO Says Regeneron Is Positioned To Deliver One Of ‘Strongest Years Ever’ After Q3 Earnings Beat

Equity

Regeneron reported a 36% surge in Q3 revenue to $5.12 billion, well above Wall Street estimates of $4.56 billion, according to Fiscal.ai


Regeneron (REGN) Reports Q3 Earnings: What Key Metrics Have to Say

The headline numbers for Regeneron (REGN) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Regeneron (REGN) Q3 Earnings and Revenues Beat Estimates

Regeneron (REGN) delivered earnings and revenue surprises of +24.81% and +12.43%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Top Wall Street Forecasters Revamp Regeneron Pharmaceuticals Expectations Ahead Of Q3 Earnings

Regeneron expects Q3 EPS of $16.19 and revenue of $4.56B; extended BARDA's Inmazeb supply deal as analysts raise price targets.read more...

Amgen Q3 Earnings: Will Strong Drug Sales Offset Headwinds?

Amgen heads into Q3 earnings with a four-quarter beat streak, but biosimilar competition, pricing pressure and higher costs may challenge growth.

Analysts Estimate Jazz Pharmaceuticals (JAZZ) to Report a Decline in Earnings: What to Look Out for

Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

$REGN Q3 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of $20.07 up 69.65% YoY
• Reported revenue of $5.12B up 36.27% YoY
• Regenerons updated 2026 guidance includes GAAP and non-GAAP gross margin on net product sales of approximately 80% and 86%, respectively, and GAAP R&amp;D of $6.6B and non-GAAP R&amp;D of $6.05B.

Stocktwits

Regeneron Pharmaceuticals, Inc.

 Q3 '26 Earnings Results & Recap

• Reported GAAP EPS of $20.07 up 69.65% YoY
• Reported revenue of $5.12B up 36.27% YoY
• Regenerons updated 2026 guidance includes GAAP and non-GAAP gross margin on net product sales of approximately 80% and 86%, respectively, and GAAP R&D of $6.6B and non-GAAP R&D of $6.05B.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

• Reported GAAP EPS of $20.07 up 69.65% YoY
• Reported revenue of $5.12B up 36.27% YoY
• Regenerons updated 2026 guidance includes GAAP and non-GAAP gross margin on net product sales of approximately 80% and 86%, respectively, and GAAP R&D of $6.6B and non-GAAP R&D of $6.05B.

Regeneron faced continued competitive pressures and patient transitions affecting EYLEA U.S. sales, lower Bayer collaboration revenue, and higher R&D expense associated with clinical pipeline advancement and manufacturing activity.

Regeneron reported rising Dupixent, EYLEA HD, and Libtayo sales, expanded Sanofi collaboration with $1B upfront and up to $7B in milestones, and received FDA approval for Pasatru.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Bullish Sentiment

<ul class="summary-bullets"><li>Adjusted EPS shot up 70% to $20.07.</li><li>U.S. sales of Eylea HD, its higher-dose injectable treatment for certain retinal diseases, jumped 62% to $699 million.</li><li>Regeneron’s collaboration revenue from Sanofi surged 68% to $2.72 billion, driven by Dupixent sales.</li></ul>Shares of Regeneron Pharmaceuticals (REGN) gained more than 8% in premarket trading on Friday, after the biotechnology firm reported stronger-than-expected third-quarter earnings, driven by growing demand for its eye treatments and higher collaboration revenue from Sanofi.If the levels hold after the opening bell, <a class="mention" data-mention="$REGN" data-symbol-id="REGN" href="https://stocktwits.com/symbol/REGN" target="_blank">REGN shares</a> would jump to their highest levels since October 2024.<h2 class="st-heading-2">Eye Treatment, Sanofi Partnership Drive Growth</h2>Regeneron reported a 36% surge in Q3 revenue to $5.12 billion, well above Wall Street estimates of $4.56 billion, according to Fiscal.ai. Adjusted earnings per share (EPS) shot up 70% to $20.07, also exceeding consensus estimates of $16.25.CFO Christopher Fenimore attributed the Q3 beat to strong sales performance across its drug portfolio and higher collaboration revenue from Sanofi.“Strong commercial execution across our portfolio, together with the anticipated step-up in Sanofi collaboration revenue in the first full quarter following repayment of the Development Balance, drove a 36% increase in total revenues and a 70% increase in non-GAAP EPS, positioning us to deliver one of our strongest years ever,” Fenimore said.U.S. sales of Eylea HD, its higher-dose injectable treatment for certain retinal diseases, jumped 62% to $699 million. However, sales of the original Eylea fell 41% as patients switched to the newer version.Regeneron’s collaboration revenue from Sanofi surged 68% to $2.72 billion, driven by strong demand for Dupixent, an inflammation treatment. Earlier this month, Regeneron and Sanofi expanded their partnership to develop four long-acting antibody treatments, with Regeneron receiving $1 billion upfront and becoming eligible for another $7 billion in future milestone payments.<h2 class="st-heading-2">FDA Decision On Cemdisiran Expected Next Month</h2>Regeneron has approximately 50 product candidates in clinical development, covering cancer, obesity, immune disorders and other diseases. The company expects a U.S. Food and Drug Administration (FDA) decision on Cemdisiran for generalized myasthenia gravis, a condition that causes muscle weakness, in November.It ended September with approximately $18.86 billion in cash and marketable securities.Regeneron raised its full-year research and development spending forecast to $6.60 billion - $6.74 billion and capital expenditure guidance to $1.05 billion - $1.10 billion.<h2 class="st-heading-2">Retail Says REGN Stock Is ‘Cheap’</h2>Retail sentiment surrounding REGN on Stocktwits remained ‘bullish’ over the past 24 hours.<img src="https://news.stocktwits-cdn.com/REGN_04f901a562.png" alt="REGN.png">One user called the stock cheap given the company’s underlying assets.<stembedurl>https://stocktwits.com/OffHisGame88/message/667738421</stembedurl>REGN shares are up nearly 15% so far in 2026.Also read:<a href="https://stocktwits.com/news-articles/markets/equity/astra-zeneca-ceo-sees-over-20b-potential-from-2027-drug-trial-readouts-azn-stock-eyes-breakout/cZUhAwOR9Th">&nbsp;AstraZeneca CEO Sees Over $20B Potential From 2027 Drug Trial Readouts – AZN Stock Eyes Breakout After Q3 Earnings Beat</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Regeneron Pharmaceuticals company logo is displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Regeneron reported a 36% surge in Q3 revenue to $5.12 billion, well above Wall Street estimates of $4.56 billion, according to Fiscal.ai

SPDR S&P Biotech ETF

Track REGN stock price, charts, news and real-time market activity on Stocktwits. Join the REGN message board to follow investor discussions, retail trader sentiment, bullish and bearish signals around Regeneron Pharmaceuticals, Inc stock.

REGN Stock Price Today - Regeneron Pharmaceuticals Inc News, Charts, Retail Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$927.89
Prev Close	$818.77
Open	$869.43
Dividend Yield	0.46%
50-Day Moving Average	$793.30
Beta	0.62
Avg. Volume	732,249.28
PE Ratio	22.93

52-Week High	$935.35
52-Week Low	$591.52
Market Capitalization	$95.51B
EPS (Annual)	$41.48
Price to Book	3.03
Revenue Per Employee	$930,752.76

Feed

News

Sentiment

Earnings

Fundamentals

Info

REGN Fundamentals